DC 159A

Drug Profile

DC 159A

Alternative Names: DC-159; DC-159a

Latest Information Update: 15 May 2008

Price : $50

At a glance

  • Originator Daiichi Sankyo Company
  • Class
  • Mechanism of Action DNA gyrase inhibitors; DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Bacterial infections; Community-acquired pneumonia; Tuberculosis

Most Recent Events

  • 13 May 2008 Discontinued - Preclinical for Tuberculosis in Japan (PO)
  • 13 May 2008 Discontinued - Preclinical for Community-acquired pneumonia in Japan (PO)
  • 13 May 2008 Discontinued - Phase-I for Bacterial infections in European Union (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top